Psilocybin and psilocin clinical trials

TRIP - TReatment to Improve Depression and/or Anxiety Using Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy M.D. Anderson Cancer Center · 2026-09-11 · NCT06200155 A Randomized Double-blinded Controlled Trial for the Treatment of Persisting Symptoms After Concussion With Psilocybin-assisted Therapy: A Safety and Feasibility Trial University of Calgary · 2026-09-09 · NCT06615908 A Double Blind, Randomized Trial Investigating the Safety, Feasibility, and Mechanisms of Psychedelics in Healthy Older Adults With Low Well-being as Moderated by Biomarkers for Preclinical Alzheimer's Disease Jennifer Mitchell · 2026-09-09 · NCT07386730 Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence University of Calgary · 2026-09-08 · NCT06885996 Effects of Psilocybin in Obsessive Compulsive Disorder Johns Hopkins University · 2026-09-04 · NCT05546658 Pilot Study of Serotonin 2A Receptor (5-HT2A) Agonist Psilocybin for Depression in Patients With Mild Cognitive Impairment or Early Alzheimer's Disease Johns Hopkins University · 2026-09-04 · NCT04123314 Psilocybin and Affective Function in Chronic Lower Back Pain Depression Johns Hopkins University · 2026-09-04 · NCT06355414 Psilocybin and MDMA for Post-traumatic Stress Disorder (PTSD) Johns Hopkins University · 2026-09-04 · NCT06989957 A Phase 2b/3, Multicentre, Randomised, Double-blind, Controlled Trial, With an Open Label Extension, to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder COMPASS Pathways · 2026-09-04 · NCT07570654 Study of Psilocybin Assisted Psychotherapy to Address Fear of Recurrence in Patients Diagnosed With Early-stage Breast Cancer and Ovarian Cancer in Remission University of Colorado, Denver · 2026-09-04 · NCT06430541 Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study Joshua Woolley, MD, PhD · 2026-09-03 · NCT04932434 High vs. Low-Dose Group-Based Psilocybin-Assisted Therapy (PAT) With or Without Mindfulness-Based (MB) Preparation and Integration for Demoralization in Adults With Advanced Cancer (PAT-MIND): A Pilot Feasibility 2x2 Factorial Multisite Trial University of Calgary · 2026-09-02 · NCT07791901 Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use Disorder NYU Langone Health · 2026-09-02 · NCT06349083 The Role of the Subjective Experience in Supporting Positive Effects Following Psilocybin: a Randomized, Controlled Clinical Trial Using Risperidone in Healthy Adults University of Calgary · 2026-09-02 · NCT06768944 Psilocybin-Assisted Therapy for Physician Well-Being and Burnout: Feasibility, Safety, Clinical Effectiveness and Biomarkers of Response [PAT-B (Psilocybin-Assisted Therapy for Physician Well-Being and Burnout)] University of California, San Diego · 2026-09-02 · NCT06814522 PRISMatic: A Phase 1b Randomized, Double-Armed, Parallel-Group, Placebo-Controlled Trial of Psilocybin Efficacy With or Without Pimavanserin Pretreatment Johns Hopkins University · 2026-08-31 · NCT07610135 NeuroGuard: Psilocybin Trial for Preventing Chemo-induced Neuropathy M.D. Anderson Cancer Center · 2026-08-31 · NCT07227909 An 8-week Phase 2 Clinical Trial to Evaluate the Safety, Tolerability and Efficacy of Psilocybin-assisted-psychotherapy in Adults With Cannabis Use Disorder: A Proof-of-Concept Study McMaster University · 2026-08-31 · NCT06225232 Psilocybin-Assisted Psychotherapy for Posttraumatic Stress Disorder in Military Veterans: A Pilot Feasibility Study ARQ National Psychotrauma Centre · 2026-08-28 · NCT07792538 A Randomised, Placebo Controlled Trial of Psilocybin in Treatment Resistant Depression: A Feasibility Study King's College London · 2026-08-28 · NCT04959253 Evaluating the Role of Psilocybin Monitors in Psilocybin Therapy for Treatment Resistant Depression: A Pilot Randomized Clinical Trial Centre for Addiction and Mental Health · 2026-08-21 · NCT07211438 Targeting Reward Circuits: Psilocybin as a Novel Therapy for Residual Anhedonia NYU Langone Health · 2026-08-20 · NCT07607938 Psilocybin in the Treatment of Methamphetamine Use Disorder Peter Hendricks · 2026-08-19 · NCT07774702 Psilocybin in Chronic Low Back Pain: An Integrative Study of Lab-Based Mechanisms and Real-World Physical Therapy Outcomes Yale University · 2026-08-19 · NCT07306364 An Exploratory Pilot Study of Palliadelic Treatment to Reduce Psychological Distress in People With Pancreatobiliary and Other Advanced Gastrointestinal Cancers University of Nebraska · 2026-08-19 · NCT05220046 An Examination of Psilocybin Effects on Biomarkers of Longevity, Healthy Aging, and Purpose in Life Charles Raison · 2026-08-17 · NCT07719088 The Therapeutic Potential of Psilocybin in Anorexia Nervosa in Young Adults Region Skane · 2026-08-14 · NCT07169747 Safety for Home Administration of Microdose Psilocybin Use Johns Hopkins University · 2026-08-14 · NCT06450210 Psilocybin Administration With 5-HT1a Blockade Johns Hopkins University · 2026-08-14 · NCT07565493 A Multi-site Randomized Controlled Trial of Psilocybin for Treatment-Resistant Depression (TRD) in Veterans VA Office of Research and Development · 2026-08-14 · NCT07226232 Role of Experience, Conscious Awareness, and Plasticity in Psilocybin's Behavioral Effects - Follow-Up Study (The RECAP 2 Study) University of Wisconsin, Madison · 2026-08-13 · NCT06692192 Processing Intergenerational Trauma With Psilocybin-Assisted Therapy Rachel Yehuda · 2026-08-13 · NCT06899165 The Effects of Psilocybin on Self-Focus and Self-Related Processing in Major Depressive Disorder Sharmin Ghaznavi · 2026-08-13 · NCT06247839 PsiloStudy: A Phase 2 Single-site, Double-blind, Placebo-controlled, Randomized Clinical Trial With an Open-label Extension Phase to Examine the Safety, Subjective Experiences, Acute Effects, and Suitability of Psilocybin Combined With Psychological Support (Psi-PS) for Military Veterans and First Responders With Co-occurring Alcohol Use Disorder (AUD) and Posttraumatic Stress Disorder (PTSD) Nathan Brashares Sackett · 2026-08-13 · NCT06853912 Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized Trial Brigham and Women's Hospital · 2026-08-13 · NCT07296094 TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors M.D. Anderson Cancer Center · 2026-08-12 · NCT06801041 Acceptability & Safety of Two Sequential Doses of Psilocybin in Bipolar Disorder II Depression and Suicidality The University of Texas Health Science Center, Houston · 2026-08-12 · NCT06706232 Low-Dose Psilocybin Therapy for Palliative Care Patients With Chronic Cancer Pain Requiring Opioids Roswell Park Cancer Institute · 2026-08-12 · NCT06827054 A Phase 2a, Placebo-Controlled Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder Claudio N Soares · 2026-08-12 · NCT06969170 Psilocybin Recovery Intervention for Stopping Methamphetamine Use Nicky Mehtani, MD, MPH · 2026-08-11 · NCT07756736 Effects of Psilocybin in Patients With Amyotrophic Lateral Sclerosis Johns Hopkins University · 2026-08-11 · NCT06656702 An Investigation of Strategies to Understand and Optimize the Antidepressant Effects of Psilocybin (The OPTIMIZE Study) Charles Raison · 2026-08-10 · NCT06512194 A Phase III, Multicentre, Randomised, Double-blind, Controlled Study to Investigate the Efficacy, Safety, and Tolerability of Two Administrations of COMP360 in Participants With Treatment-resistant Depression COMPASS Pathways · 2026-08-10 · NCT05711940 Safety, Tolerability, Outcomes of Psilocybin for Depression (STOP Depression) in Veterans With Spinal Cord Injury James J. Peters Veterans Affairs Medical Center · 2026-08-10 · NCT07251491 A Phase III, Multicentre, Randomised, Double-blind, Placebo-controlled Study to Investigate the Efficacy, Safety, and Tolerability of COMP360 in Participants With Treatment-resistant Depression COMPASS Pathways · 2026-08-10 · NCT05624268 A Multicenter Phase 1 Safety and Tolerability Trial of Psilocybin in Healthy Older Adults University of Colorado, Denver · 2026-08-10 · NCT07516405 Neurobiological Effects of Psilocybin in Treatment Resistant Bipolar Depression: An Emotional-Processing fMRI Pilot Study University Health Network, Toronto · 2026-08-10 · NCT06506019 Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin (NECTAR) in Aging and Alzheimer's Disease National Institute on Aging (NIA) · 2026-08-07 · NCT07721467 The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease Joshua Woolley, MD, PhD · 2026-08-07 · NCT06455293 Open Label Psilocybin Brain Stimulation and Imaging Pilot Study Johns Hopkins University · 2026-08-07 · NCT06835699 Single Dose Psilocybin for a Post-surgical Trauma Inpatient Population for Pain, Mood, and Opioid Use Disorder Trent Emerick · 2026-08-06 · NCT07406828 Psilocybin for Treatment-Resistant Depression in Autism: a Pilot Trial With Pre-Post Brain and Cognitive Measurement to Understand Mechanism Centre for Addiction and Mental Health · 2026-08-06 · NCT06731621 An Exploratory Study of Feasibility, Efficacy, and Mechanisms of Mindfulness-Assisted Psychedelic Therapy University of Southern California · 2026-08-06 · NCT06233344 Feasibility Phase 2 Study of Psilocybin-Assisted Therapy for Opioid-Refractory Pain in Patients With Advanced Cancer Yvan Beaussant, MD, MSci · 2026-08-05 · NCT06001749 Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies University of New Mexico · 2026-08-04 · NCT07745569 Psilocybin as a Treatment for Chronic Pain in Smokers Yale University · 2026-08-03 · NCT07118332 Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study Oregon Health and Science University · 2026-08-03 · NCT06988319 A Phase 2a Study of Group Retreat Psilocybin Therapy for Cancer-Related Anxiety and Depression University of Washington · 2026-07-31 · NCT07336238 Psilocybin-Assisted Group Integration Psychotherapy for Treatment-Resistant Depression Joshua Rosenblat · 2026-07-30 · NCT07737990 Trauma-informed Psilocybin Assisted Psychotherapy (TiPAP) for Post-Traumatic Stress Disorder Tel-Aviv Sourasky Medical Center · 2026-07-30 · NCT07737054 Imaging the Effects of Serotonin 2A Receptor Modulation on Synaptic Density in Treatment-resistant Depression (SYNVEST) Centre for Addiction and Mental Health · 2026-07-30 · NCT06512220 Treatment With Psilocybin for Chronic Neuropathic Pain and Depression (TRANSCEND): An Open-Label Clinical Trial Centre for Addiction and Mental Health · 2026-07-30 · NCT06518720 An Open-Label, Phase 1 Study of the Safety Pharmacokinetic Profile, and Preliminary Efficacy, of Organic Whole Psilocybin-Containing Mushrooms in Patients Suffering From PTSD Scottsdale Research Institute · 2026-07-29 · NCT07275970 Activating Neuroplasticity to ENHANCE the Perception Box Expanding Effects of Psilocybin University of Wisconsin, Madison · 2026-07-29 · NCT05866471 Changes in Self-awareness Induced by Psychoactive Substances: an Experimental Study With Psilocybin. Pontifícia Universidade Católica do Rio de Janeiro · 2026-07-28 · NCT07732166 Evaluating the Feasibility, Clinical Effects, and Safety of Psilocybin-assisted Psychotherapy for Treatment-resistant Obsessive-compulsive Disorder: An Open-label Clinical Trial Centre for Addiction and Mental Health · 2026-07-28 · NCT06299319 A Randomized Double-masked Dose-controlled Trial to Assess the Tolerability, Safety, Subjective Experience, and Efficacy of Repeated Administration of Three Different Doses of Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder. Francisco A Moreno · 2026-07-23 · NCT07347405 Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought Johns Hopkins University · 2026-07-23 · NCT05301608 Probing the Functional Magnetic Resonance Imaging Response to Psilocybin in Functional Neurological Disorder (PsiFUND) King's College London · 2026-07-23 · NCT05723276 A Phase 3, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Psilocybin in Adults With Major Depressive Disorder (MDD) Usona Institute · 2026-07-23 · NCT06308653 A Randomized, Double-Blind, Placebo-Controlled Mechanistic Study to Assess a Single Oral Dose of CYB003 in Participants With Major Depressive Disorder (MDD) and Moderate to Severe Anxiety Ohio State University · 2026-07-23 · NCT06820723 The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease Yale University · 2026-07-20 · NCT07610369 A Randomized, Double-Blind, Single Ascending Dose Study to Identify a Safe and Non-Psychedelic Dose of Psilocybin Diamond Therapeutics Inc. · 2026-07-17 · NCT07710027 Outpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial Johns Hopkins University · 2026-07-17 · NCT06067737 Effect of Psilocybin and Structured Integrated Reframing Therapy on Gut-Brain Axis Biomarkers and Depression in Trauma-Related Major Depressive Disorder: Randomized Controlled Trial Khyber Medical University Peshawar · 2026-07-14 · NCT07703722 Mechanistic Studies of Psilocybin in Headache Disorders Yale University · 2026-07-13 · NCT06464367 PSilocybin Microdose for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site Phase 3 Double-blind, Placebo-controlled, Parallel-arm Clinical Trial Bruyère Health Research Institute. · 2026-07-10 · NCT07063862 PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL): A Multi-site, Open-label, Single Arm Phase I/II Proof-of-concept, Dose-finding, and Feasibility Clinical Trial Ottawa Hospital Research Institute · 2026-07-10 · NCT04754061 Investigating the Mechanisms of the Effects of Psilocybin on Visual Perception and Visual Representations in the Brain University of California, Berkeley · 2026-07-10 · NCT05265546 The Effects of Psilocybin on Social Connectedness Yale University · 2026-07-09 · NCT07693153 Psilocybin-Assisted Psychotherapy for Treatment-Resistant Depression: A Randomized Phase II Clinical Trial Comparing One Versus Two Psychedelic Doses of Psilocybin (PSI-1V2) University Health Network, Toronto · 2026-07-09 · NCT06341426 Computationally, Electrophysiologically, and Qualitatively Characterizing Serotonergic Psychedelics; Transdiagnostic Therapeutic and Pro-Psychotic Effects Yale University · 2026-07-09 · NCT06624137 Psilocybin: Capturing Brain Mechanisms of Motivation and Neurocognition in Individuals With Opioid Use Disorder University of Pennsylvania · 2026-07-09 · NCT06810310 Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on a Buprenorphine/Naloxone Formulation University of Wisconsin, Madison · 2026-07-07 · NCT04161066 Exploration of Synaptotrophic Effects of Psilocybin in Opioid Use Disorder (OUD) Yale University · 2026-07-07 · NCT06160284 Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study University of Wisconsin, Madison · 2026-07-02 · NCT07360301 Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive Symptoms Centre Hospitalier Universitaire de Nīmes · 2026-07-01 · NCT07638553 A Phase 2, Open-Label Study Investigating the Safety and Efficacy of Psilocybin-Assisted Therapy for Sexual Assault-Related Posttraumatic Stress Disorder (PTSD) Sunstone Medical · 2026-07-01 · NCT06902974 5-HT2A Agonist Psilocybin in the Treatment of Tobacco Use Disorder Johns Hopkins University · 2026-06-29 · NCT05452772 Psilocybin-Assisted Massed Cognitive Processing Therapy for Chronic Posttraumatic Stress Disorder: An Open-label Trial Unity Health Toronto · 2026-06-26 · NCT06386003 Acute Effects of MDMA Co-administration on the Response to Psilocybin in Healthy Subjects University Hospital, Basel, Switzerland · 2026-06-25 · NCT06884514 A Pilot Mechanistic RCT of Psilocybin With Mindfulness-based Therapy vs Support for Posttraumatic Stress Disorder (PTSD) Anthony P King · 2026-06-25 · NCT07104916 Effects of Psilocybin Microdosing on Cognition, Mood and Quality of Life: A Pilot Study Yale University · 2026-06-23 · NCT07449351 Psilocybin-assisted Existential, Attachment and Relational (PEARL) Therapy for Caregivers of Patients With Advanced Cancer: A Phase II Open-Label Trial University Health Network, Toronto · 2026-06-23 · NCT07048743 Psilocybin-Assisted Therapy for Prolonged Grief University of Virginia · 2026-06-23 · NCT06724289 Psilocybin for PTSD With or Without Psychotherapy: A Pilot Study of Safety and Efficacy Johns Hopkins University · 2026-06-22 · NCT06407635 Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer: A Phase II Open-Label Trial University Health Network, Toronto · 2026-06-22 · NCT06416085 The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function Manoj Doss · 2026-06-15 · NCT07079852 Multivariate Neural and Physiological Correlates of Psychedelic Sub-states: a Within-subjects, Healthy Volunteer Study With Experience-sampling Robin Carhart-Harris, PhD, MA · 2026-06-05 · NCT05698511 Effects of Repeated Dosing of Psilocybin on Obsessive-Compulsive Disorder: A Randomized, Waitlist-Controlled Study Yale University · 2026-06-04 · NCT05370911 2 x 2 Factorial, Double-blind, Randomized Trial of 'Set and Setting': a Translational Study in Healthy Volunteers Robin Carhart-Harris, PhD, MA · 2026-06-04 · NCT06626139 The Safety and Acceptability of Psilocybin With Support and With Massed Prolonged Exposure Therapy for PTSD Emory University · 2026-05-26 · NCT07332143 Effects of Psilocybin With Psychological Support on Anhedonia in Treatment-resistant Depression: a Randomized Controlled Pilot Trial University of Colorado, Denver · 2026-05-22 · NCT06230757 Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder University of New Mexico · 2026-05-22 · NCT07506395 A Pilot Mechanistic Study of Psilocybin-Assisted Therapy as a Treatment for Depression Washington University School of Medicine · 2026-05-20 · NCT07582120 Psilocybin-assisted Cognitive Behavioral Therapy for Depression University of California, Los Angeles · 2026-05-19 · NCT05227612 Psilocybin-facilitated Treatment for Cocaine Use University of Alabama at Birmingham · 2026-05-18 · NCT02037126 Exploring the Safety, Acceptability, and Efficacy of Psilocybin Among Non-Small Cell Lung Cancer Patients With Major Depressive Disorder: A Proof-of-Concept Trial (DREAM LUNG STUDY) Alan Davis · 2026-05-14 · NCT07216404 Psilocybin for Treatment of Obsessive Compulsive Disorder Francisco A Moreno · 2026-05-12 · NCT06992999 Safety and Feasibility of Psilocybin in Methamphetamine Use Disorder in a Community-Based Sample University of Wisconsin, Madison · 2026-05-12 · NCT05322954 The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD. University Medical Center Groningen · 2026-05-08 · NCT06782724 Does Psilocybin Require Psychedelic Effects to Treat Depression? A 4-Week, Double-Blind, Proof-of-Concept Randomized Controlled Trial Centre for Addiction and Mental Health · 2026-05-07 · NCT05710237 A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of up to Two Doses of Psilocybin for the Treatment of Major Depressive Disorder in Adults With Cancer Sunstone Medical · 2026-05-06 · NCT05947383 Induction Protocol for Psilocybin-Assisted Therapy in Treatment-Resistant Depression (TRD): A Pilot Study University of North Carolina, Chapel Hill · 2026-05-06 · NCT06303739 A Phase 2 Randomized Study Examining the Safety, Feasibility, and Effectiveness of Masking Psilocybin Therapy With General Anesthesia in Major Depressive Disorder Stanford University · 2026-05-06 · NCT07479550 A One-Year Observational Follow-up Study of Participants With Major Depressive Disorder Following a Randomized, Double-Blind Single-Dose of Psilocybin or Niacin-Control Usona Institute · 2026-05-04 · NCT04353921 A Phase 2 Sequential Dose-Finding Study of Preparation for Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression University of Washington · 2026-05-04 · NCT07565909 Group Psilocybin-assisted Cognitive Behavioral Therapy for Major Depressive Disorder University of California, Los Angeles · 2026-05-04 · NCT07566104 Psilocybin-Assisted Therapy for Treatment-Resistant Depression in Bipolar II Disorder: A Randomized Controlled Trial Lakshmi N Yatham · 2026-05-01 · NCT06943573 Lysergic Acid Diethylamide (LSD) in Palliative Care: a Randomised, Double-blind, Active-placebo Controlled Phase II Study (LPC-Study) University Hospital, Basel, Switzerland · 2026-04-29 · NCT05883540 A Double-blind, Randomized Trial Examining the Preliminary Efficacy of Psilocybin Therapy for People With Chronic Low Back Pain Joshua Woolley, MD, PhD · 2026-04-29 · NCT05351541 Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder Portland VA Research Foundation, Inc · 2026-04-22 · NCT04982796 A Randomized, Double-Blind Study of Single-Dose Psilocybin for Major Depressive Disorder (MDD) Usona Institute · 2026-04-22 · NCT03866174 Toward Patient-Tailored Care for Treatment-Resistant Depression: A Pilot Patient-Preference Clinical Trial of Music and Mindfulness in Psilocybin-Assisted Psychotherapy Kyle Greenway · 2026-04-22 · NCT07373535 CAPSI - Cancer Related Major Depression Treated With a Single Dose of Psilocybin: A Multicenter Randomized Placebo Controlled Double Blind Clinical Trial Section for Affective Disorders; Northern Stockholm Psychiatry · 2026-04-13 · NCT06319378 Safety Profile of 25 mg Psilocybin in Individuals With Cocaine Use Disorder University of California, Los Angeles · 2026-04-07 · NCT06102434 Acute Analgesic Effects of DMT on Experimentally Induced Acute Nociceptive Pain, Hyperalgesia and Allodynia in Healthy Participants University Hospital, Basel, Switzerland · 2026-04-02 · NCT06180759 Engaging Mood Brain Circuits With Psilocybin: a Randomized Neuroimaging Trial in Depression Sunnybrook Health Sciences Centre · 2026-03-30 · NCT06072898 Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder Indiana University · 2026-03-30 · NCT07499583 Psilocybe Cubensis Mushrooms With or Without Fluoxetine for Refractory Depression Federal University of Latin American Integration · 2026-03-27 · NCT06898606 The QUANTUM Trip Trial - Psilocybin-assisted Therapy for Reducing Alcohol Intake in Patients With Alcohol Use Disorder: A Randomized, Double-blinded, Placebo-controlled Clinical Trial. Anders Fink-Jensen, MD, DMSci · 2026-03-24 · NCT05416229 Elucidating the Relevance of the Psychedelic Experience to Psilocybin's Anti-Anhedonic Effects: A Randomized, Open-Label, Cross-Over Functional Magnetic Resonance Imaging Trial Medical University of Vienna · 2026-03-24 · NCT07490353 Precision Phenotyping of Behavioral Risk and Response to Electromagnetic and Psychedelic Therapies University of New Mexico · 2026-03-20 · NCT07484906 Pilot Study of Psilocybin-assisted Treatment for Cannabis Use Disorder Johns Hopkins University · 2026-03-18 · NCT06660381 Safety and Efficacy of Psilocybin-assisted Psychotherapy for Demoralization Syndrome in Patients Diagnosed With Advanced Stage Cancer: a Pilot Study Gustavo Vazquez · 2026-03-18 · NCT06818994 Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder Johns Hopkins University · 2026-03-13 · NCT04620759 Exploratory Study of the Effects of Low-Dose Psilocybin on Sensory Processing, Neurophysiological Arousal, and Emotional Health University of Alabama at Birmingham · 2026-03-11 · NCT05227742 Psilocybin-facilitated Treatment for Chronic Pain University of Alabama at Birmingham · 2026-03-11 · NCT05068791 Safety, Feasibility, and Tolerability of Psilocybin Treatment for Individuals With Functional Impairment Related to Mood, Anxiety, Trauma and/or Addiction Symptoms: An Open-label Proof-of-concept Study Yale University · 2026-03-11 · NCT06442423 Pilot Proof of Concept Study Evaluating the Potential Psilocybin Assisted Psychotherapy (PAP) as a Therapeutic Tool for Patients Suffering From Severe Irritable Bowel Syndrome. NYU Langone Health · 2026-03-05 · NCT06760533 Examining the Safety and Clinical Efficacy of Psilocybin Therapy for Veterans With PTSD: An Open-Label Proof-of-Concept Trial Ohio State University · 2026-03-04 · NCT05554094 A Phase 2b Double-blind, Randomized, Low-dose Comparator-controlled Clinical Trial to Assess the Efficacy and Safety of NPX-5 in Psilocybin-assisted Psychotherapy for the Treatment of Adjustment Disorder Associated With Cancer. Psyence Australia Pty Ltd · 2026-03-03 · NCT07072728 Study of Psilocybin for Anorexia in Young Adults Marissa Raymond-Flesch, MD, MPH · 2026-03-03 · NCT06399263 Does Psilocybin Change Synaptic Density in the Brains of Patients With Amnestic Mild Cognitive Impairment Centre for Addiction and Mental Health · 2026-02-25 · NCT06041152 The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers. Gabriella Gobbi · 2026-02-25 · NCT07433452 Inpatient Buprenorphine Induction With Psilocybin for Opioid Use Disorder: a Randomized Double-blind Trial Johns Hopkins University · 2026-02-23 · NCT06005662 Investigation of Psychedelic Effects in Psychoactive Substances Johns Hopkins University · 2026-02-23 · NCT06772753 Pilot Study of Psilocybin-Assisted Therapy for Demoralization in Patients Receiving Hospice Care - PATH Study Yvan Beaussant, MD, MSci · 2026-02-17 · NCT04950608 A Phase 1 Translational Study to Assess Brain Activity Using Functional Magnetic Resonance Imaging (fMRI) and to Evaluate the Safety, Tolerability, and Pharmacokinetics of Multiple Doses of MLS101 (Psilocybin) in Healthy Volunteers MycoMedica Life Sciences PBC · 2026-02-13 · NCT07050368 Psychedelic Healing: Adjunct Therapy Harnessing Opened Malleability Johns Hopkins University · 2026-02-13 · NCT07053917